Ultivue develops innovative reagent-based solutions that maximize the biological information available from cells and tissue samples. The company's technology is being used to elucidate biological pathways and to validate clinically-relevant biomarkers. Ultivue is based in Cambridge, MA. Our culture provides an exceptional work environment fostering innovation and collaboration to make a difference collectively. Ultivue’s employees are bright, flexible, and driven to create meaningful impact through our work. We work at a fast pace, but support each other achieve the work/life balance that helps us thrive as a company. Our entrepreneurial culture relies on contributions and input from all. Our bench of experienced managers provides mentoring and support to ensure front line staff make the most of their unique talents and energy. Open Positions Ultivue provides unique opportunities for talented individuals to bring all of themselves--their passion, expertise and creativity--to bear on collectively solving problems that matter. For the full list of open positions and to apply please visit our website https://www.ultivue.com/careers. When submitting job application, make sure to submit both a resume and a cover letter.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $97.15M
Founded date: 2015
Investors 2
Date | Name | Website |
17.07.2021 | ARCH Ventu... | archventur... |
- | Applied Ma... | appliedmat... |
Funding Rounds 4
Date | Series | Amount | Investors |
27.04.2021 | Series D | $50M | - |
27.06.2019 | Series C | $22M | - |
24.01.2018 | Series B | $20M | ARCH Ventu... |
13.10.2015 | Series A | $5.15M | - |
Mentions in press and media 18
Date | Title | Description |
22.08.2024 | Accelerating Translational Research with High-Performance Automated InSituPlex® Assays, Upcoming Webinar Hosted by Xtalks | www.ultivue.com In this free webinar, learn how the InSituPlex biomarker detection assays facilitate high-confidence biomarker analysis with enhanced sensitivity and specificity. Attendees will discover the simplicity of the workflow while ... |
11.06.2024 | Investigating Cell Therapy Efficacy Mechanisms in Solid Tumors by Spatial Immunophenotyping, Upcoming Webinar Hosted by Xtalks | www.ultivue.com In this free webinar, learn how spatial immunophenotyping assays are being used to understand the whole tumor microenvironment in patient biopsy samples. Attendees will learn how multiplex immunofluorescence (mIF) assays can... |
30.06.2022 | Importance of Spatial Distribution Insight from Clinical Biopsies, Upcoming Webinar Hosted by Xtalks | Today, spatial biology is finally giving researchers much needed contextual information resolving cells and biomarkers. TORONTO (PRWEB) June 30, 2022 Current immuno-oncology research is revealing diagnostic, prognostic and predictive cell s... |
05.08.2021 | Fluidigm : Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million | Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corp... |
27.04.2021 | Ultivue : Announces $50M Financing Round | Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue phenotyping, today announced the completion of a $50 million Ser... |
27.06.2019 | Ultivue Raises $22 Million in Series C Funding | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, the innovation leader in tissue biomarker identification and quantification assays for translational and pathology research labs, today announced the close of a $22 Million Series C funding led by... |
27.06.2019 | Ultivue Raises $22M in Series C Funding | Ultivue, a Cambridge, Mass.-based leader in tissue biomarker identification and quantification assays for translational and pathology research labs, closed a $22M Series C funding. The round was led by new investor Northpond Ventures with p... |
27.06.2019 | Ultivue Raises $22 Million in Series C Funding | - |
24.01.2018 | Ultivue Completes $20M Series B Funding | CAMBRIDGE, MA, Ultivue has announced that it has closed a $20 million Series B funding round led by existing investor ARCH Venture Partners. >> Click here for more funding data on Ultivue >> To export Ultivue funding data to... |
23.01.2018 | ARCH Venture Leads $20M Series B for Ultivue | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, has announced today that it has closed a $20 million Series B funding round led by exi... |
Show more